Boston Scientific Corporation (NYSE:BSX) agreed to acquire the remaining stake in Millipede Inc. from Santé Health Ventures II, L.P. managed by Santé Ventures, LLC for $450 million on December 27, 2018. Out of total consideration, $325 million will be paid at closing and $125 million will be payable upon achievement of a commercial milestone. BSX expects the deal to close in first quarter of 2019. The deal is expected to cut adjusted EPS for several years but the dilutive impact will be absorbed by internal trade-offs. Boston Scientific Corporation (NYSE:BSX) completed the acquisition of remaining stake in Millipede Inc. from Santé Health Ventures II, L.P. managed by Santé Ventures, LLC on January 29, 2019. The transaction was subject to antitrust regulations and was completed following the expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976.